S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
ASTH · Astrana Health Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$37.31
-1.28
(-3.30%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$37.31
$37.30
$38.73
52-WEEK RANGE
$37.31
$18.08
$51.60
What's happening
- ASTH is down 3.30% today, trading at $37.31. — Live quote
- Volume today (6,450) is well below its 3-month average of 522,039. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.40 actual vs. $0.34 estimated (+16.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 8
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
ASTH
+48.73%
vs S&P 500
+36.33%
1-YEAR RETURN
ASTH
+15.28%
vs S&P 500
-0.09%
6-MONTH RETURN
ASTH
+26.24%
3-MONTH RETURN
ASTH
-17.17%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$0.40
Est. $0.34
BEAT +16.7%
2026-04-26 (Q1 2026)
$0.29
Est. $0.30
MISS -4.9%
2026-01-26 (Q4 2025)
$0.12
Est. $0.11
BEAT +11.0%
2025-10-26 (Q3 2025)
$0.01
Est. $0.45
MISS -97.8%
Valuation Measures & Ratios
Enterprise Value4$2.39B
Forward P/E519.49
PEG Ratio60.80
Price / Sales (TTM1)0.48
Price / Book72.77
EV4 / Revenue0.62
EV4 / EBITDA14.10
Profit Margin1.05%
Operating Margin2.76%
Return on Equity (ROE8)5.09%
Return on Assets (ROA9)1.78%
Avg Volume (3M)522,039
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.29B | $1.22B | $1.05B | $1.23B | $1.48B |
| P/E | 52.08 | 39.47 | 32.38 | 24.03 | 26.11 |
| Price/Sales | 0.65 | 0.38 | 0.39 | 0.55 | 0.75 |
| Price/Book | 2.76 | 1.53 | 1.36 | 1.61 | 1.99 |
| EV/Revenue | 0.80 | 0.55 | 0.61 | 0.58 | 0.82 |
| EV/EBITDA | 18.12 | 13.26 | 13.12 | — | — |
| ROE | 5.30% | 3.86% | 4.20% | 6.71% | 7.62% |
| ROA | 1.93% | 1.31% | 1.46% | 3.56% | 4.27% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,087,127
Change from Prior Settlement-5.68%
% of Float—
Days to Cover (Short Ratio)5.80
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 48.5% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +15.3%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is 1.1%. Finnhub fundamentals ↗
- Trailing P/E is 45.7, a high price relative to reported earnings. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ASTH
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $972.5M | $965.1M | $956.0M | $654.8M | $620.4M | $478.7M | $486.3M | $404.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $34.3M | $28.5M | $19.2M | $20.3M | $20.6M | $28.4M | $30.1M | $30.1M |
| Net income | $19.7M | $14.4M | $373.0K | $9.4M | $6.7M | $16.1M | $19.2M | $14.8M |
| EPS (diluted) | $0.40 | $0.29 | $0.01 | $0.19 | $0.14 | $0.33 | $0.40 | $0.31 |
| EPS (basic) | $0.40 | $0.30 | $0.01 | $0.19 | $0.14 | $0.34 | $0.40 | $0.31 |
| Operating margin | $4 | $3 | $2 | $3 | $3 | $6 | $6 | $7 |
| Net margin | $2 | $1 | $0 | $1 | $1 | $3 | $4 | $4 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $2.28B | $2.36B | $2.22B | $2.24B | $1.44B | $1.33B | $1.35B | $1.29B |
| Total liabilities | $1.68B | $1.78B | $1.66B | $1.68B | $904.4M | $813.5M | $840.7M | $778.3M |
| Stockholders' equity | $830.2M | $800.3M | $779.3M | $775.5M | $765.5M | $745.4M | $712.7M | $704.6M |
| Total current assets | $919.2M | $1.00B | $863.3M | $883.6M | $729.2M | $613.3M | $638.5M | $597.0M |
| Total current liabilities | $747.6M | $745.4M | $615.3M | $629.9M | $459.7M | $361.3M | $365.6M | $312.9M |
| Cash & equivalents | $400.8M | $478.4M | $429.5M | $462.2M | $339.7M | $258.5M | $288.5M | $348.0M |
| Marketable securities (current) | — | — | — | $1.2M | $2.4M | $2.4M | $2.4M | $2.4M |
| Accounts receivable | $465.1M | $467.4M | $374.5M | $381.2M | $348.7M | — | $276.0M | — |
| Property, plant & equipment | $62.6M | $59.5M | $57.3M | — | — | — | $14.3M | — |
| Goodwill | $887.0M | $874.8M | $865.3M | $863.3M | $416.9M | $416.4M | $419.3M | $409.7M |
| Intangible assets | $243.3M | $257.1M | $271.0M | $285.1M | $105.7M | $111.9M | $118.2M | $109.1M |
| Other non-current assets | $27.6M | $26.8M | $25.4M | $23.4M | $30.4M | $30.5M | $16.7M | $8.9M |
| Accounts payable | — | — | — | — | — | — | — | — |
| Deferred revenue (current) | — | — | $2.7M | — | — | $686.0K | $1.6M | $2.2M |
| Short-term debt | $53.8M | $47.9M | $47.9M | $47.9M | $12.5M | $12.5M | $9.4M | $15.0M |
| Other current liabilities | $17.4M | $23.1M | $24.5M | $21.8M | $29.8M | $28.2M | $27.5M | $30.4M |
| Long-term debt | $882.6M | $979.8M | $990.9M | $1.00B | $401.1M | $403.9M | $425.3M | $423.1M |
| Other non-current liabilities | $10.4M | $18.8M | $17.1M | $15.9M | $12.3M | $14.7M | $14.6M | $7.5M |
| Common stock & paid-in capital | $49.0K | $49.0K | $49.0K | $49.0K | $49.0K | $49.0K | $48.0K | $48.0K |
| Retained earnings | $342.4M | $322.7M | $308.4M | $302.5M | $302.2M | $292.9M | $286.3M | $293.2M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $32.7M | $68.1M | -$2.9M | $10.0M | $90.9M | $16.6M | -$10.9M | $34.0M |
| Investing cash flow | -$6.2M | -$2.8M | -$1.1M | -$534.5M | -$1.1M | -$2.4M | -$33.3M | -$8.1M |
| Financing cash flow | -$104.1M | -$16.0M | -$26.3M | $648.5M | -$8.6M | -$44.2M | -$15.3M | -$3.2M |
| Free cash flow | $28.9M | $64.1M | -$6.0M | $7.4M | $89.5M | $13.6M | -$13.5M | $31.7M |
| Capital expenditures | $3.9M | $4.0M | $3.1M | $2.6M | $1.4M | $3.1M | $2.5M | $2.3M |
| Depreciation & amortization | $15.5M | $15.5M | $16.4M | $15.6M | $6.9M | $6.8M | $8.1M | $7.3M |
| Share-based compensation | $11.8M | $9.9M | $11.4M | $7.7M | $11.7M | $7.8M | $15.2M | $6.2M |
| Deferred income taxes | — | — | -$4.3M | — | — | — | -$4.2M | — |
| Change in accounts receivable | — | — | -$944.0K | — | — | $10.4M | -$2.2M | -$85.0K |
| Purchases of investments | — | — | — | — | — | $24.0K | $27.0K | $27.0K |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Other investing activities | -$1.4M | -$1.2M | -$2.1M | -$3.2M | -$343.0K | -$676.0K | $27.0K | -$97.0K |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | $0 | $2.8M | $15.0M | $0 | $0 | $10.6M | $900.0K | $0 |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $2.7M | $1.2M | $607.0K | $509.0K | $1.0M | $4.1M | $687.0K | $391.0K |
| Other financing activities | -$5.0M | $189.0K | $3.2M | -$937.0K | $1.2M | -$1.2M | $1.1M | -$386.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $3.18B | $2.03B | $1.39B | $1.14B | $773.9M |
| Gross profit | — | — | — | — | — |
| Operating income | $78.5M | $89.3M | $84.6M | $104.3M | $98.2M |
| Net income | $22.5M | $43.1M | $60.7M | $45.2M | $68.9M |
| EPS (diluted) | $0.46 | $0.90 | $1.29 | $0.99 | $1.52 |
| EPS (basic) | $0.46 | $0.91 | $1.30 | $1.00 | $1.57 |
| Operating margin | $2 | $4 | $6 | $9 | $13 |
| Net margin | $1 | $2 | $4 | $4 | $9 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $2.22B | $1.35B | $933.4M | $966.2M | $852.4M |
| Total liabilities | $1.66B | $840.7M | $522.6M | $407.7M | $336.4M |
| Stockholders' equity | $779.3M | $712.7M | $614.2M | $542.6M | $454.6M |
| Total current assets | $863.3M | $638.5M | $461.5M | $428.1M | $398.8M |
| Total current liabilities | $615.3M | $365.6M | $218.7M | $148.6M | $115.4M |
| Cash & equivalents | $429.5M | $288.5M | $293.8M | $288.0M | $233.1M |
| Marketable securities (current) | — | $2.4M | $2.5M | $5.6M | $53.4M |
| Accounts receivable | $374.5M | $276.0M | — | $52.6M | $10.6M |
| Property, plant & equipment | $57.3M | $14.3M | — | — | — |
| Goodwill | $865.3M | $419.3M | $278.8M | $269.1M | $246.4M |
| Intangible assets | $271.0M | $118.2M | $71.6M | $76.9M | $82.8M |
| Other non-current assets | $22.5M | $16.7M | $1.9M | $4.6M | $5.9M |
| Accounts payable | — | — | — | — | — |
| Deferred revenue (current) | $2.7M | $1.6M | $744.0K | $531.0K | $16.8M |
| Short-term debt | $47.9M | $9.4M | $19.5M | $619.0K | $780.0K |
| Other current liabilities | $24.5M | $27.5M | $18.9M | $0 | — |
| Long-term debt | $990.9M | $425.3M | $258.9M | $203.4M | $182.9M |
| Other non-current liabilities | $17.1M | $14.6M | $3.6M | $20.3M | $14.8M |
| Common stock & paid-in capital | $49.0K | $48.0K | $47.0K | $47.0K | $45.0K |
| Retained earnings | $308.4M | $286.3M | $243.1M | $182.4M | $143.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $114.6M | $52.2M | $68.2M | $82.1M | $70.3M |
| Investing cash flow | -$539.0M | -$192.4M | -$65.5M | -$7.1M | $16.5M |
| Financing cash flow | $569.3M | $135.1M | $3.4M | -$20.1M | -$47.7M |
| Free cash flow | $104.5M | $44.2M | $39.7M | $59.2M | $51.1M |
| Capital expenditures | $10.1M | $8.0M | $28.5M | $22.9M | $19.2M |
| Depreciation & amortization | $45.7M | $27.9M | $17.7M | $17.5M | $17.5M |
| Share-based compensation | $38.6M | $34.5M | $22.0M | $16.1M | $6.7M |
| Deferred income taxes | -$4.3M | -$4.2M | -$12.4M | -$14.3M | $7.7M |
| Change in accounts receivable | $9.4M | $35.8M | $20.6M | $38.2M | $1.5M |
| Purchases of investments | — | $109.0K | $2.2M | $1.9M | $28.0M |
| Other investing activities | -$6.3M | $2.2M | $3.7M | — | — |
| Dividends paid | — | — | — | — | — |
| Share repurchases | $25.6M | $900.0K | $10.2M | $9.2M | $5.7M |
| Debt issued | — | — | — | — | — |
| Debt repaid | — | — | — | — | — |
| Tax withholding on stock comp | $6.2M | $4.7M | $0 | $0 | — |
| Other financing activities | $2.3M | $466.0K | $769.0K | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ASTH as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-26 to 2026-10-10
Recent transactions
- Most recent: Vong John (SVP - Accounting (PAO)) — Tax withholding of 556 shares on 2026-10-10.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Vong John | SVP - Accounting (PAO) | Tax withholding | 2026-10-10 | 556 |
| Sim Brandon | CEO and President | Tax withholding | 2026-10-06 | 9,889 |
| Lam Thomas S. | Director | Tax withholding | 2026-10-06 | 2,624 |
| Basho Chandan | COO and CFO | Tax withholding | 2026-10-02 | 2,092 |
| Kitayama Mitchell W | Director | Disposition to issuer | 2026-08-31 | 8,500 |
| Schmidt David | Director | Option exercise | 2026-08-14 | 20,000 |
| Sobotka Glenn | Former Officer | Disposition to issuer | 2026-08-07 | 11,793 |
| Mazdyasni Matthew | Director | Grant / award | 2026-06-10 | 4,525 |
| Dong Linda | Director | Grant / award | 2026-06-10 | 4,525 |
| Dai, Weili | Director | Grant / award | 2026-06-10 | 4,525 |
| Chiang John | Director | Grant / award | 2026-06-10 | 4,525 |
| Sim Kenneth T. | Executive Chairman | Grant / award | 2026-04-06 | 100,000 |
| Kumar Dinesh M. | Chief Medical Officer | Grant / award | 2026-04-01 | 35,300 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-10 | Vong John | SVP - Accounting (PAO) | Tax withholding | 556 | $37.55 |
| 2026-10-06 | Sim Brandon | CEO and President | Tax withholding | 9,889 | $37.00 |
| 2026-10-06 | Lam Thomas S. | Director | Tax withholding | 2,624 | $37.00 |
| 2026-10-02 | Basho Chandan | COO and CFO | Tax withholding | 2,092 | $35.88 |
| 2026-09-15 | Vong John | SVP - Accounting (PAO) | Tax withholding | 96 | $38.35 |
| 2026-09-05 | Sim Brandon | CEO and President | Tax withholding | 7,163 | $38.47 |
| 2026-09-05 | Basho Chandan | COO and CFO | Tax withholding | 1,790 | $38.47 |
| 2026-08-31 | Kitayama Mitchell W | Director | Disposition to issuer | 8,500 | $37.09 |
| 2026-08-14 | Schmidt David | Director | Option exercise | 20,000 | $5.00 |
| 2026-08-14 | Schmidt David | Director | Disposition to issuer | 20,000 | $38.59 |
| 2026-08-07 | Sobotka Glenn | Former Officer | Disposition to issuer | 11,793 | $0.00 |
| 2026-06-27 | Sim Brandon | CEO and President | Tax withholding | 1,093 | $44.51 |
| 2026-06-10 | Schmidt David | Director | Grant / award | 4,525 | $0.00 |
| 2026-06-10 | Mazdyasni Matthew | Director | Grant / award | 4,525 | $0.00 |
| 2026-06-10 | Kitayama Mitchell W | Director | Grant / award | 4,991 | $0.00 |
| 2026-06-10 | Dong Linda | Director | Grant / award | 4,525 | $0.00 |
| 2026-06-10 | Dai, Weili | Director | Grant / award | 4,525 | $0.00 |
| 2026-06-10 | Chiang John | Director | Grant / award | 4,525 | $0.00 |
| 2026-05-16 | Basho Chandan | COO and CFO | Tax withholding | 8,155 | $38.26 |
| 2026-04-14 | Basho Chandan | COO and CFO | Tax withholding | 3,870 | $29.07 |
| 2026-04-06 | Lam Thomas S. | Director | Grant / award | 41,667 | $0.00 |
| 2026-04-06 | Sim Kenneth T. | Executive Chairman | Grant / award | 100,000 | $0.00 |
| 2026-04-06 | Sim Brandon | CEO and President | Grant / award | 201,056 | $0.00 |
| 2026-04-02 | Basho Chandan | COO and CFO | Tax withholding | 2,092 | $25.05 |
| 2026-04-01 | Kumar Dinesh M. | Chief Medical Officer | Grant / award | 35,300 | $0.00 |
| 2026-04-01 | Kumar Dinesh M. | Chief Medical Officer | Tax withholding | 57,980 | $24.51 |
| 2026-03-26 | Sobotka Glenn | Chief Accounting Officer | Tax withholding | 662 | $24.27 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 00:35 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 4 | 2026-10-10 | View on SEC.gov → |
| 2026-10-08 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-08 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-06 | 4 | 2026-10-02 | View on SEC.gov → |
| 2026-09-23 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-09-23 | 8-K | 2026-09-22 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-09-15 | 8-K | 2026-09-15 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-05 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-05 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-14 | View on SEC.gov → |
Recent news
Headlines about ASTH (Astrana Health Inc.). Links open the publisher — we don’t host full articles.
-
Astrana Health, Inc. (ASTH) stock price, news, quote and history
Yahoo Finance UK · 2026-10-21 -
How Investors May Respond To Alignment Healthcare (ALHC) New Medicare Plan
Yahoo · 2026-10-19 -
Astrana Health (ASTH), What Is Behind The Fresh Attention?
Simply Wall Street · 2026-10-19 -
ASTH261016C00035000 Interactive Stock Chart | ASTH Oct 2026 35.000 call Stock
Yahoo Finance · 2026-10-19 -
Alignment Health Plan and Astrana Health Partner to Expand Access to Trusted Local Care for California Seniors
Yahoo · 2026-10-19 -
Astrana Health Inc. (ASTH) Stock Forecasts
Yahoo! Finance Canada · 2026-10-17 -
Astrana Health, Inc. (ASTH) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16 -
2 of Wall Street’s Favorite Stocks to Target This Week and 1 We Ignore
Yahoo · 2026-10-16
No headlines in this category right now — try “All”.